2004
DOI: 10.1002/cyto.b.20030
|View full text |Cite
|
Sign up to set email alerts
|

Diminished expression of CD19 in B‐cell lymphomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
26
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 58 publications
(27 citation statements)
references
References 33 publications
1
26
0
Order By: Relevance
“…We have demonstrated that evaluating the intensity of staining for CD19 can help in this differential diagnosis. It has been previously shown that decreased CD19 antigen expression is seen more frequently in follicular lymphoma than in other lymphoma subtypes (16,21). Our results confirm this finding and specifically demonstrate that there is a significantly lower MCF value for CD19 in FL cases as compared to MZL cases.…”
Section: Discussionsupporting
confidence: 90%
“…We have demonstrated that evaluating the intensity of staining for CD19 can help in this differential diagnosis. It has been previously shown that decreased CD19 antigen expression is seen more frequently in follicular lymphoma than in other lymphoma subtypes (16,21). Our results confirm this finding and specifically demonstrate that there is a significantly lower MCF value for CD19 in FL cases as compared to MZL cases.…”
Section: Discussionsupporting
confidence: 90%
“…The prognostic significance of CD20 expression is contentious in other lymphoma subtypes and, to our knowledge, has never been specifically examined in DLBCL. 6,[26][27][28][29] We demonstrate that patients who have reduced CD20 expression but bright CD19 expression (discordant CD20) on their biopsies taken at diagnosis have a markedly inferior OS after treatment with CHOP with or without rituximab, independent of the IPI.…”
Section: Discussionmentioning
confidence: 72%
“…While CD19 is thought to be a very useful lineage defining antigen for B cells, decreased or absent CD19 expression can be seen in B cell malignancies (1). Decreased or absent CD19 is more common in follicular lymphoma or DLBCL, but aberrant decrease or loss can occur in a variety of B lineage neoplasms (1,2). CD20 is also typically seen in mature B cells, though decreased CD20 expression is a classic immunophenotypic aberrancy of the neoplastic B cells comprising a CLL/SLL clone (3).…”
Section: Discussionmentioning
confidence: 99%